摘要
目的观察替米沙坦治疗前、后高血压合并糖尿病患者血清脂联素水平的变化。方法将50名门诊高血压合并糖尿病病人分为替米沙坦和氨氯地平两组。观察治疗前及治疗10周后患者血压、脂联素及血糖、胰岛素变化。结果与治疗前相比,替米沙坦组与氨氯地平组收缩压和舒张压均显著降低(P<0.01),替米沙坦组血清脂联素水平较治疗前显著升高(P<0.01),血糖、胰岛素和胰岛素抵抗较治疗前显著降低(P<0.01);氨氯地平组治疗前后血清脂联素、血糖、胰岛素和胰岛素抵抗无明显改变(P>0.05)。结论与氨氯地平相比,替米沙坦在降压的同时,显著增高了血清脂联素水平并显著改善胰岛素抵抗,显示其具有降压外良好的代谢效应。
Aim To investigate the effect of telmisartan on adiponectin in hypertensive patients with type 2 diabetes mellitus. Methods In this prospective study, 50 hypertensive patients with type 2 diabetes mellitus were treated either with telmisartan or with amlodipine for 10 weeks. The serum concentration of fasting adiponectin, glucose, insulin and blood pressure （BP） were measured at baseline and after treatment respectively. Results The systolic and diastolic BP decreased significantly after the treatment both in telmisartan group and in amlodipine group. In telmisartan group, serum adiponectin was significandy increased, but blood glucose, insulin and insulin resistance （ IR） were significantly decreased （ P 〈 0.01 ） ; But no notable difference was detected in adiponectin, blood glucose, insulin in amlodipine group （ P 〉 0.05 ）. Conclusion These data indicated the potential effect of telmisartan on the improvement of adiponectin and IR, which demonstrate the metabolic effect of telmisartan beyond its BP reduction.
出处
《中国动脉硬化杂志》
CAS
CSCD
2008年第6期492-494,共3页
Chinese Journal of Arteriosclerosis
作者简介
陈远刚，硕士研究生，主治医师。通讯作者陈明。副教授，硕士研究生导师，主要研究方向为肾素-血管紧张素系统及肾素-血管紧张素阻断剂在心血管病中的作用，E-mail为chenmingcq@yahoo．com.
